Coexistence of tubulocystic renal cell carcinoma and polycythemia vera: A rare case report

Abstract

Tubulocystic Renal Cell Carcinoma (TC-RCC) and Polycythemia Vera (PV) are both infrequent medical conditions. TC-RCC was recognized as a distinct subtype of kidney cancer by the World Health Organization in 2016, while PV is a rare myeloproliferative neoplasm distinguished by the excessive production of red blood cells. The coexistence of these two conditions is exceptionally uncommon and lacks comprehensive documentation. This study presents a case report of a 35-year-old male patient who has been diagnosed with PV for the past 20 years. The patient underwent a radical nephrectomy to remove the renal tumor, and subsequent histopathological analysis confirmed the presence of TC-RCC. Throughout the 6-month follow-up period, the patient exhibited no signs of abnormalities. The rarity of the coexistence of TC-RCC and PV highlights the intricate nature of managing such instances, necessitating a cautious approach to diagnosis and treatment, particularly in surgical interventions. The present study serves as a valuable resource for diagnosing and treating individuals presenting with concurrent renal neoplasms and PV.

Introduction

Tubulocystic renal cell carcinoma (TC-RCC), first described by Amin et al. in 2004, was recognized as a rare subtype of renal cancer by the World Health Organization (WHO) in 2016.^1,2 TC-RCC is predominant in individuals with a mean age of 55.7 years, with a male-to-female ratio of 5:1.^2–4 Most patients are asymptomatic upon admission, but occasional symptoms include gross hematuria, abdominal pain, or distension. It exhibits a favorable prognosis and has low metastasis potential.

Polycythemia Vera (PV) is a rare myeloproliferative neoplasm with an annual incidence rate of 0.4–2.8/100,000 individuals. ⁵ It is characterized by excessive red blood cell production, which often leads to increased white blood cells and platelets, thus causing increased blood viscosity and volume. Almost all patients with PV have Janus kinase 2 (JAK2; 9p24) mutations, with 96 and 3% of patients having a mutation in exon 14 (JAK2 V617F) and 12, respectively.^6,7 PV can lead to peripheral neuropathy, manifesting symptoms such as headache, dizziness, and ataxia. Other complications, including myelofibrosis, severe anemia, hypoalbuminemia, deep vein thrombosis, and refractory infections, may occur in advanced stages. ⁸

This study presents a unique case involving both TC-RCC and PV, which, to our knowledge, has not been previously documented. With the emphasis on the rarity of these diseases, accurate diagnosis and effective treatment are necessary.

Case

A 35-year-old man with a 16-day history of recurrent gross hematuria and left flank pain was admitted to the West China Fourth Hospital (Figure 1). The patient did not experience any symptoms, such as nausea, vomiting, fever, or lower urinary tract symptoms. He had a previous diagnosis of PV 20 years ago, which was treated with oral hydroxyurea and transfer factor for 9 years. Physical examination revealed massive erythema and papules in the body and limbs. Hematological analysis revealed red blood cell count of 7.11 × 10¹²/L (normal range: 4.0–5.8 × 10¹²/L), hemoglobin (Hb) level of 197 g/L (normal range: 120–175 g/L), and hematocrit (Hct) of 61.6% (normal range: 40–50%), white blood cell and platelet count within the normal range, and increased activated partial thromboplastin time by 5 s, with other coagulation indices within normal limits.

Figure 1.

Case timeline: diagnosis and treatment overview.

Three urinary cytologic examinations detected no tumor cells. Computed tomographic urography (CTU) identified a parenchymal alteration adjacent to the renal pelvis (Figure 2). In light of the patient’s gross hematuria, a flexible ureterorenoscopy was performed to comprehensively examine the entirety of the left upper urinary tract. No exophytic lesions were observed except for extravasated blood from the renal pelvis mucosa and a few small clots within the renal pelvis.

Figure 2.

In CTU, both coronal (A) and transverse sections (B) show a solid mass located in the middle near the upper pole of the left kidney, next to the renal pelvis.

In compliance with tumor size and location, as well as patient preferences, a left radical laparoscopic nephrectomy was performed. Postoperatively, aspirin (100 mg/day) was administered for 1 week, which was discontinued after 1 week and replaced with low molecular weight heparin (5000 IU/daily subcutaneous injection) as a bridging agent to reduce the risk of thrombotic events during the perioperative period.

The dimensions of the surgical specimen and the length of the ureter segment were 13 × 7 × 5.7 cm and 5.5 cm, respectively. A nodular neoplasm of 5 × 4 × 3 cm size in the middle upper pole of the kidney was identified (Figure 3). The tumor cut surface exhibited a spongy texture, distinct boundary, and gray-white color.

Figure 3.

Macroscopic view shows the tumor located at mid-upper pole of kidney, adjacent to the renal collecting system.

Microscopically, the tumor regions exhibited a comprehensive tubulocystic configuration devoid of any solid, papillary, or cribriform architectural features (Figure 4). The composition encompassed tubules of diverse dimensions, spanning from diminutive to moderate, alongside dilated tubules housing cysts. These tubules were surrounded by a hypocellular and fibrotic stroma. The cellular lining of the surface displayed a varying layer, ranging from flat to cuboidal to hobnailed. Predominantly, abundant pink cytoplasm and large nuclei with prominent nucleoli (indicating a nucleolar grade three by the WHO/ISUP classification) having no perinucleolar halos were observed in cells.

Figure 4.

The tubules and cysts are delineated by a uniform layer of epithelial cells, displaying a variety of morphologies including flat and hobnail to cuboidal and columnar. The majority of cells feature copious eosinophilic cytoplasm. (Haematoxylin and Eosin staining (HE), magnification ×400 (A), magnification ×100 (B).).

Tumor invasion was not observed in the ureter or renal sinus, and there was no evidence of vascular or perineural invasion, lymph node metastasis, sarcomatoid or rhabdoid features, or invasion in the capsule and perinephric fat.

Immunohistochemical staining confirmed the diagnosis and revealed tumor cell positive results for CA-IX (focal+), PAX-8 (+), vimentin (+), P504S (+), AMACR (+), SDHB (+), FH (+), Ki-67 (+, approximately 25%), and CK (AE1/AE3) (focal+), while negative results for CD10 (−), CK (−), CK20 (−), WT1 (−), HMB45 (−), CD57 (−), TFE3 (−), and HCK (−).

The analysis of morphological characteristics and immunohistochemistry confirmed the diagnosis of TC-RCC, with tumor staging classified as pT1bN0M0. Following a successful recovery, the patient was discharged with a recommendation for ongoing monitoring. A subsequent 6-month follow-up revealed no signs of tumor or hematuria recurrence, with normal levels of Hb and Hct.

Discussion

TC-RCC remains a rare disease, with less than 100 cases reported worldwide.^3,4 Due to its rarity, there is a lack of research examining the demographic features or risk factors associated with TC-RCC. Imaging examinations, such as CT or magnetic resonance imaging, provide limited diagnostic insights into TC-RCC ⁹ due to its resemblance with adult cystic nephroma and mixed epithelial and stromal tumors, both exhibiting multilocular cystic manifestations. ¹⁰ TC-RCC cases have been reported to impact either the renal cortex or the corticomedullary junction, potentially resulting in gross hematuria in patients. ¹¹ Additionally, the proximity of the neoplasm to the renal pelvis indicates that urothelial malignancy should be considered as a potential differential diagnosis before obtaining pathology results. To determine the surgical extent and obtain a biopsy for definitive diagnosis, invasive diagnostic methods, including the use of a flexible ureteroscope, are considered appropriate.

The clinical symptoms of PV often include fatigue, headaches, pruritus, and nocturnal diaphoresis, with some patients also exhibiting hematuria. ¹² PV therapy is aimed at reducing the incidence of thrombotic events, which can be achieved through therapeutic phlebotomy, low-dose aspirin therapy, and various cytoreductive therapies. ⁸ When the patient cannot tolerate or respond adequately to phlebotomy, which is the primary treatment for managing PV, hydroxyurea can be considered a first-line treatment option. In our case, the patient did not respond adequately to phlebotomy; therefore, long-term oral hydroxyurea chemotherapy was administered to achieve cytoreduction and symptom control. However, patients with PV have a higher risk of developing secondary malignancies, and they often exhibit elevated levels of pro-inflammatory cytokines, including interleukin-6, tumor necrosis factor-α, and C-reactive protein, which play a significant role in tumor development and progression. Rampant inflammation may also lead to poor treatment outcomes, potentially facilitating the progression and poor prognosis of renal carcinoma. ¹³ The prognosis is even worsen for patients with end-stage PV with concurrent renal malignancies. Several studies on patients receiving chemotherapy, radiotherapy, or targeted therapy have indicated that albumin can serve as a prognostic biomarker in cancer patients, with lower albumin levels associated with a higher risk of mortality or disease progression. ¹⁴ Moreover, patients with end-stage PV may present with cachexia and low albumin levels, along with an increased burden on the liver due to myeloproliferation and hepatotoxic effects of hydroxyurea and interferon. ⁸ It results in reduced albumin synthesis capacity and decreased plasma albumin levels, leading to a poorer prognosis. Beyond treatment, quality of life is an important focus for such patients. ¹⁵

TC-RCCs are characterized by an average size of 4 cm and classified as indolent or having low metastatic potential, indicating that surgical interventions could be beneficial for most patients with TC-RCC.^2–4 Given the T1b tumor stage of our patient, radical nephrectomy is the preferred treatment option, although nephron-sparing surgery remains a viable alternative for T1b-stage tumors. ¹⁶ The immunohistochemical findings following surgery demonstrate a positive expression of FH markers, which suggests a low risk of progression. ¹⁷ However, cases involving large masses, multiple lesions, or metastases have also been reported.^2,4,11 The current knowledge and treatment strategies are inadequate in effectively managing the TC-RCC recurrence and metastatic potential. We conducted a comprehensive literature review and found that only a few studies have documented the use of adjuvant treatment, which are summarized in Table 1.

Table 1.

Summary of studies on adjuvant treatment for TC-RCC cases.

Author(s)	Number of cases (n)	Gender (M/F)	Mean age	Size of tumor (mean and range) (cm)	Stage	Adjuvant treatment	Metastasis
Amin et al. 2	31	27/4	54	4.2 (0.7–17)	pT1 (24 patients); pT2 (4 patients); pT3 (3 patients)	Adjuvant chemotherapy* (3 patients)	Local (1 patient), liver and bone (2 patient)
Bhullar et al. 18	1	1/0	33	10.1 × 8.0	NA	Sorafenib	Bone and peritoneum
Hora et al. 19	1	5/0	56	5.8 (5.1–6.5)	pT1 (4 patients); pT3 (1 patient)	Gemcitabine, cisplatin, sunitinib (1 patient); temsirolimus, sunitinib (1 patient)	Pleura, retroperitoneum and mediastinal lymph nodes (1 patient); sternum, ribs and mediastinal lymph nodes (1 patient)
Sangle et al. 20	1	1/0	45	4.5	pT3	Adjuvant chemotherapy*	Brain, paraspinal tissue, peritoneal sidewall and adrenal gland
Banerjee et al. 21	1	0/1	45	14.6 × 10.8 × 14.6	NA	Sunitinib, Everolimus	Peritoneum and omentum
Urabe et al. 22	1	1/0	51	9.2 × 6 × 5.4	pT2a	Sunitinib, Axitinib, Temsirolimus	Lung and bone
Salvatori et al. 23	1	1/0	70	NA	pT3	Pazopanib, Nivolumab	Left hypochondrium, liver and bone

NA: not available; M: male; F: Female.

*

Drug specifics not detailed in the article.

The combination of these two rare diseases has prompted some reflections. For PV patients with advanced-stage renal carcinoma, subsequent consideration of chemotherapy, immunotherapy, and targeted therapy is warranted. These treatments can have certain side effects, including peripheral neuropathy. Additionally, using PV treatments, such as hydroxyurea, can significantly increase the risk of developing this condition, potentially leading to difficult-to-manage symptoms such as headaches and neuropathic pruritus. ²⁴ In such cases, simultaneous adjustment of treatment plans for both diseases may be necessary, highlighting the importance of collaboration among oncologists, urologists, and hematologists.

Currently, there are few cases of TC-RCC and a lack of international collaboration, resulting in a paucity of research on molecular mechanisms. More therapeutic targets need exploration, with future research focusing on developing adjuvant therapeutic drugs with fewer side effects.^24,25 Additionally, the direct link between JAK2 mutations and renal cancer remains unrecognized, with most studies focusing on the role of JAK2 mutations in hematologic malignancies. A few studies suggest that inhibiting the JAK2/STAT3 pathway may suppress the proliferation, invasion, and migration of renal cancer cells, while also promoting apoptosis within these cells.^26,27 Exploring the potential efficacy of JAK2 inhibitors in renal cancer treatment could provide a dual-effective regimen for patients with PV and renal cancer, thereby offering greater benefits.

Conclusion

The rare coexistence of TC-RCC and PV highlights the complex nature of managing such conditions, necessitating a cautious approach to diagnosis and treatment, particularly in surgical interventions. Our case study provides a reference for physicians for managing simultaneous renal neoplasms and PV. However, additional research is necessary to explore the interaction and mechanisms underlying the coexistence of PV and renal cancer, aiming to develop optimal treatment strategies.